A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy. - Has extensive-stage SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition. - Submits an archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated where such sample exist. - Prior therapy with the following NOT permitted: anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, anti-CTLA-4, anti-OX-40, anti-CD137, anti-CD27).

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Erin Schenk,  MD, PhD

Erin Schenk, MD, PhD

Study ID

Protocol Number: 21-3726

More information available at ClinicalTrials.gov: NCT04924101

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers